logo Creation made simple
Beautifully designed
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut convallis tempor orci vitae vehicula. Aliquam in ullamcorper lacus.
Follow & share
Search:
Infallible Pharma | IFPP INJECTION 40 MG
20951
portfolio_page-template-default,single,single-portfolio_page,postid-20951,edgt-core-1.0.1,ajax_fade,page_not_loaded,,hudson-ver-1.8, vertical_menu_with_scroll,smooth_scroll,side_menu_slide_from_right,blog_installed,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

IFPP INJECTION 40 MG

IFPP INJECTION 40 MG


Brand Name : IFPP-40


Generic Name : Pantoprazole for Injection BP 40 mg


Pack Size : Vial + WFI


Dosage Form : Powder for Injection


Strength : 40 mg


Therapeutic indications : – Reflux oesophagitis
– Gastric and duodenal ulcer
– Zollinger-Ellison-Syndrome and other pathological hypersecretory conditions.


Pharmacotherapeutic group : Drugs for acid related disorders, Proton pump inhibitors


ATC code : A02BC02


Pharmacodynamic properties : Pantoprazole is a substituted benzimidazole which inhibits the secretion of hydrochloric acid in the stomach by specific action on the proton pumps of the parietal cells.
Pantoprazole is converted to its active form in the acidic environment in the parietal cells where it inhibits the H+, K+-ATPase enzyme, i. e. the final stage in the production of hydrochloric acid in the stomach. The inhibition is dose-dependent and affects both basal and stimulated acid secretion. In most patients, freedom from symptoms is achieved within 2 weeks. As with other proton pump inhibitors and H2 receptor inhibitors, treatment with pantoprazole reduces acidity in the stomach and thereby increases gastrin in proportion to the reduction in acidity. The increase in gastrin is reversible. Since pantoprazole binds to the enzyme distal to the cell receptor level, it can inhibit hydrochloric acid secretion independently of stimulation by other substances (acetylcholine, histamine, gastrin). The effect is the same whether the product is given orally or intravenously.

Date

February 12, 2022

Share